Topics

Takeda looks to adopt value-based pricing for expensive treatments

06:37 EDT 30 Apr 2019 | SmartBrief

Takeda Pharmaceutical is evaluating the profitability of Alofisel stem cell therapy, which is expected to cost $67,000, under -More

Original Article: Takeda looks to adopt value-based pricing for expensive treatments

NEXT ARTICLE

More From BioPortfolio on "Takeda looks to adopt value-based pricing for expensive treatments"

Quick Search

Relevant Topic

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...